EAN 2025: GLP-1 Therapy Shows Promise in Reducing Migraine Burden

The GLP-1 receptor agonist liraglutide, used in the treatment of type 2 diabetes, lowers brain fluid pressure. According to a new study presented at the 2025 EAN Congress, liraglutide can cut monthly migraine days by more than half.